Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph not_applicable
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

NCT06745687
not_yet_recruitingphase_2

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

NCT07652905
not_yet_recruitingphase_1

CM336 for Active Sjogren's Syndrome Study

NCT07642843

Clinical Trials (3)

Showing 3 of 3 trials
NCT06745687Not Applicable

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Recruiting
NCT07652905Phase 2

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

Not Yet Recruiting
NCT07642843Phase 1

CM336 for Active Sjogren's Syndrome Study

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3